A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
Recruiting now · Phase 1
Conditions studied: Advanced Solid Tumor
In brief
This is a first-in-human (FIH), multicenter, open-label Phase I study to investigate the safety, tolerability, preliminary antitumor activity, as well as pharmacokinetics (PK) and pharmacodynamics of XL309 (previously ISM3091) administered alone or in combination with olaparib in participants with advanced solid tumors.
Key facts
- Study ID
- NCT05932862
- Run by
- Exelixis
- People needed
- 429
- Starts
- 2024-04-03
- Expected to finish
- 2029-08-03
- Last updated by the study team
- 2025-09-05
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Exelixis Clinical Site #3 — San Antonio, Texas, United States (enrolling)
- Exelixis Clinical Site #15 — Jacksonville, Florida, United States (enrolling)
- Exelixis Clinical Site #8 — Orlando, Florida, United States (enrolling)
- Exelixis Clinical Site #16 — Tampa, Florida, United States (enrolling)
- Exelixis Clinical Site #14 — Rochester, Minnesota, United States (enrolling)
- Exelixis Clinical Site #6 — Nashville, Tennessee, United States (enrolling)
- Exelixis Clinical Site #4 — Austin, Texas, United States (enrolling)
- Exelixis Clinical Site #1 — Houston, Texas, United States (enrolling)
- Exelixis Clinical Site #9 — New Brunswick, New Jersey, United States (enrolling)
- Exelixis Clinical Site #5 — New York, New York, United States (enrolling)
- Exelixis Clinical Site #7 — Cleveland, Ohio, United States (enrolling)
- Exelixis Clinical Site #13 — Oklahoma City, Oklahoma, United States (enrolling)
- Exelixis Clinical Site #11 — Germantown, Tennessee, United States (enrolling)
- Exelixis Clinical Site #10 — Kansas City, Missouri, United States
- Exelixis Clinical Site #2 — Houston, Texas, United States
- Exelixis Clinical Site #12 — Fountain Valley, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.